1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Hodgkin’s Lymphoma - Epidemiology Forecast to 2024

EpiCast Report: Hodgkin’s Lymphoma - Epidemiology Forecast to 2024

Summary

Hodgkin’s lymphoma (HL), also known as Hodgkin’s disease, is a type of lymphoma, a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, which spreads beyond the lymphatic system and impairs the body’s immune system.

According to the American Cancer Society (ACS), HL can start anywhere in the lymphoid tissue of body, but quite often starts in the upper part of body with main sites in the neck, the chest, or under the arms. HL mostly spreads through lymph vessels to other lymph nodes, and in advanced stages can even invade the bloodstream and spread to other organs including the liver, lungs, and bone marrow. The most common symptoms of HL include enlarged lymph nodes under the skin of the neck, under the arm, or in the groin, fever (which can come and go over several days or weeks) without an infection; drenching night sweats, and weight loss.

To forecast the diagnosed incident cases and five-year diagnosed prevalent cases of HL in 7MM, GlobalData epidemiologists obtained data from population-based studies that provided country-specific data in each of the 7MM. In addition, GlobalData epidemiologists used the staging system for HL known as the Cotswold system, which is a modification of the older Ann Arbor system, to segment the diagnosed incident cases of HL in the 7MM into stages I, II, III, and IV.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of HL in the 7MM from 23,662 diagnosed incident cases in 2014 to 28,397 diagnosed incident cases in 2024 at an Annual Growth Rate (AGR) of 2%. The increase in the diagnosed incident cases of HL was partly attributed to the moderately rising trend in the incidence of HL in the 7MM, combined with changes in the population demographics in the respective markets.

Scope

- The Hodgkin’s Lymphoma (HL) EpiCast Report provides an overview of the risk factors and global trends of HL in the 7MM (US, France, Germany, Italy, Spain, UK and Japan). It includes a 10-year epidemiology forecast for the diagnosed incident cases of HL, segmented by age, sex, and clinical stage at diagnosis, and types (classical HL and nodular lymphocyte predominant HL, with classical HL further segmented into subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) in these markets. In addition, GlobalData epidemiologists provide a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HL, as well as the number of HL diagnosed incident cases refractory to chemo- and radiation therapy, the number of HL diagnosed incident cases who received autologous stem cell transplantation (ASCT), and HL diagnosed incident cases refractory to ASCT from 2014-2024 in these markets.
- The HL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hodgkin’s Lymphoma (HL) EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HL market.
- Quantify patient populations in the global HL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HL therapeutics in each of the markets covered.
- Identify the percentage of HL diagnosed incident cases by type and treatment.

Table Of Contents

EpiCast Report: Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Epidemiology 11
3.1 Disease Background 11
3.2 Risk Factors and Comorbidities 12
3.3 Global Trends 14
3.3.1 Incidence 14
3.3.2 Survival Rates for HL — 7MM 16
3.4 Forecast Methodology 17
3.4.1 Sources Used 21
3.4.2 Sources Not Used 23
3.4.3 Forecast Assumptions and Methods, HL Diagnosed Incident Cases 24
3.4.4 Forecast Assumptions and Methods, HL Five-Year Diagnosed Prevalent Cases 24
3.4.5 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Clinical Stages at Diagnosis 25
3.4.6 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Cellular Types 26
3.4.7 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to CRT ? 7MM 27
3.4.8 Forecast Assumptions and Methods, HL Diagnosed Incident Cases Who Received ASCT 27
3.4.9 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Refractory/Relapse to ASCT 28
3.5 Epidemiological Forecast for HL (2014-2024) 29
3.5.1 Diagnosed Incident Cases of HL 29
3.5.2 Age-Specific Diagnosed Incident Cases of HL 30
3.5.3 Sex-Specific Diagnosed Incident Cases of HL 32
3.5.4 Age-Standardized Diagnosed Incidence of HL 34
3.5.5 Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis 35
3.5.6 Diagnosed Incident Cases of HL by Cellular Types 36
3.5.7 Diagnosed Incident Cases of HL, Refractory/Relapse to CRT 37
3.5.8 Diagnosed Incident Cases of HL, Receiving ASCT 38
3.5.9 Diagnosed Incident Cases of HL, Refractory to ASCT 39
3.5.10 Five-Year Diagnosed Prevalent Cases of HL 40
3.6 Discussion 42
3.6.1 Epidemiological Forecast Insight 42
3.6.2 Limitations of the Analysis 42
3.6.3 Strengths of the Analysis 43
4 Appendix 44
4.1 Bibliography 44
4.2 About the Authors 47
4.2.1 Epidemiologist 47
4.2.2 Reviewers 47
4.2.3 Global Director of Therapy Analysis and Epidemiology 48
4.2.4 Global Head of Healthcare 49
4.3 About GlobalData 50
4.4 About EpiCast 50
4.5 Disclaimer 51

1.1 List of Tables
Table 1: Cotswold Modification of the Ann Arbor Staging Classification for HL 12
Table 2: Risk Factors and Comorbidities for HL 13
Table 3: Trends in the Age-Standardized Incidence of HL in the US, All Ages, 1998-2007 14
Table 4: Trends in the Age-Standardized Incidence of HL in the 5EU, All Ages, 1998-2007 15
Table 5: Trends in the Age-standardized Incidence of HL in Japan, All Ages, 1998-2007 16
Table 6: Trends in the Five-Year Relative Survival (%) of HL in the 7MM, Both Sexes, 1995-2007 17
Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast of HL Diagnosed Incident Cases 18
Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast of HL Diagnosed Five-Year Prevalent Cases 18
Table 9: 7MM, Sources of Epidemiological Data Used for the Segmentation of HL Diagnosed Incident Cases by Clinical Stage at Diagnosis 19
Table 10: 7MM, Sources of Epidemiological Data Used for the Segmentation of HL Diagnosed Incident Cases by Cellular Type 19
Table 11: 7MM, Sources of Epidemiological Data Used to Segment HL Diagnosed Incident Cases Refractory to CRT 20
Table 12: 7MM, Sources of Epidemiological Data Used to Segment HL Diagnosed Incident Cases Who Received ASCT 20
Table 13: 7MM, Sources of Epidemiological Data Used to Segment HL Diagnosed Incident Cases Refractory ASCT 20
Table 14: 7MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2014-2024 29
Table 15: 7MM, Age-Specific Diagnosed Incident Cases of HL, Both Sexes, N (Row %), 2014 31
Table 16: 7MM, Sex-Specific Diagnosed Incident Cases of HL, All Ages, N (Row %), 2014 33
Table 17: 7MM, Five-Year Diagnosed Prevalent Cases of HL, Both Sexes, All Ages, N, 2014-2024 41

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2014-2024 30
Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of HL, Both Sexes, N, 2014 32
Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of HL, All Ages, N, 2014 34
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of HL (Cases per 100,000 Population), All Ages, by Sex, 2014 35
Figure 5: 7MM, Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 36
Figure 6: 7MM, Diagnosed Incident Cases of HL by Cellular Types, All Ages, Both Sexes, N, 2014 37
Figure 7: 7MM, Diagnosed Incident Cases of HL, Refractory to CRT, Both Sexes, All Ages, N, 2014 38
Figure 8: 7MM, Diagnosed Incident Cases of HL, Receiving ASCT, Both Sexes, All Ages, N, 2014 39
Figure 9: 7MM, Diagnosed Incident Cases of HL, Refractory/Relapse to ASCT, Both Sexes, All Ages, N, 2014 40
Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of HL, Both Sexes, All Ages, N, 2014-2024 41

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.